Emmvee Photovoltaic — a fast boat in a flooded harbour
Emmvee Photovoltaic Power Limited
A note on the data. Emmvee listed only in November 2025, so there are no annual reports to read yet and no long filed history — the public record is one DRHP, two concall transcripts (Q2 and Q3 FY26), and a screener snapshot that now carries a full FY26 year. I’ve leaned on those, and tagged the thinner bits. Treat the deep-history judgements (10-year RoE consistency, capital-allocation track record through cycles) as provisional — we simply don’t have the decade of public numbers a Buffett read normally rests on.
Snapshot
Emmvee makes solar panels — and, more importantly, the solar cells that go inside them (a cell is the silicon wafer that turns sunlight into electricity; a module is the finished panel of many cells). It is one of only a handful of Indian firms that make both under one roof, using the newer, higher-efficiency TOPCon technology. Market cap ₹22,993 cr, share ₹332 (as of 2026-06-20), 52-week range ₹172–₹354, P/E 21.3, P/B 6.2 (book value ₹53.4), RoE 51.1%, RoCE 44.8%, no dividend to speak of. What kind of animal is it? A capital-hungry, fast-growing manufacturer riding a powerful policy tailwind in a commodity industry that is busily building far too much capacity. As of 2026-06-20, from screener snapshot.
The verdict in two boxes — the business first, the price second
Keep them apart on purpose. Box 1 is what kind of business this is — it would read the same if the share price doubled or halved tomorrow. Box 2 is only what Mr. Market is charging for it today.
Box 1 — The business (durable):
| Lens | Result |
|---|---|
| Business-quality score | 14.5 / 23 (Quality 7.5/12 · Growth 5/6 · Longevity 2/5) |
| Buffett rubric | 4 / 10 PASS (3 PASS, 2 PARTIAL, 5 FAIL) |
| Business bucket | Good (high returns today, but heavy capital appetite to grow) |
| Wealth-creator type | Transitory-tilted · Volatile (policy-and-cycle-driven, too short a record to call Enduring) |
| Economic Profit | +₹1,444 cr (RoE 51.1% − CoE 12% on ₹3,694 cr net worth) — creating real value right now |
A Good business — a low-cost, well-run operator earning genuinely uncommon returns at this moment — that is not yet proven to be a durable wealth creator, independent of what it costs today. The returns are real; the question is how long the industry lets it keep them.
Box 2 — The price today (a current phenomenon):
| Reading | Result |
|---|---|
| CMP | ₹332 (as of 2026-06-20) |
| Price pillar | 1 / 2 (PEG ~0.85x on a sane forward 25% · 5-yr payback ~1.8–2.4x) |
| Margin-of-safety band | ₹180–₹250 (where the 5-yr payback feel approaches ~1x and PEG sits clearly below 1x on normalised growth) |
| Mr. Market’s mood now | Fair-to-warm. Re-rated hard off the ₹172 low on the ALMM-cell tailwind; not euphoric (the IPO listed flat), not fearful |
| CMP vs the band | Above the band — Demanding but not absurd. ~21x trailing earnings is undemanding for the growth, if the growth and the margin both hold |
Today the market prices it fairly-to-slightly-rich — a mood built on the June-2026 cell-mandate tailwind and a clean post-IPO balance sheet. That mood can cool fast if module prices crack or the cell glut arrives early, while the business in Box 1 doesn’t change at all.
In plain English
Imagine a country that has decided, by law, to build an enormous amount of solar power — and then decided that, from June 2026, the most important part of the panel, the cell, must be made in India to qualify for government-backed projects. That single rule turns Indian-made solar cells from a nice-to-have into a must-have. Emmvee is one of the few companies that already makes cells, at scale, using the good technology. That is the whole bull story in one breath: the right factory, in the right country, at the right moment.
And the numbers it has put up are eye-watering. Three years ago Emmvee earned ₹9 cr of profit. This past year (FY26) it earned ₹1,082 cr on ₹5,050 cr of sales, at a 34% operating margin. RoE is over 50%. After the IPO it paid off almost all its debt — borrowings fell from ₹2,065 cr to ₹360 cr. On paper, this is a rocket.
But here is the catch, and it’s a big one. Solar manufacturing is a commodity business. A panel from Emmvee and a panel from a dozen rivals do roughly the same job, and the price of a panel has fallen by more than 90% over two decades — the CEO himself says modules sold for €3 a watt in 2006 and sell for 15 US cents today. The only thing that has kept Emmvee’s margins fat is that cells are still scarce in India (the country has ~210 GW of panel-making capacity but only ~27 GW of cell capacity). The whole industry can see that gap and is racing to fill it. India’s cell capacity could roughly quintuple in three years. When that happens — and in a commodity, it always happens — the fat margins get competed away. Emmvee’s own management is admirably blunt about this: they tell you to ignore the percentage margin and watch the absolute profit-per-watt, because the per-watt selling price will keep falling. That is the honest language of a price-taker, not a brand.
So the moat is thin and partly rented from the government: the ALMM rule and the import duty are the walls, and walls a regulator builds, a regulator can move. Emmvee’s own edge — three decades of operating experience, a genuinely excellent quality record (warranty claims under 0.008%), a blue-chip customer list, and a low-cost, fast-execution culture — is real and worth something. It is the reason Emmvee earns more per watt than the new entrants. But it is the difference between a good operator and a great franchise, not a substitute for one.
The tension between the two boxes, then, is unusual. This isn’t “a wonderful business at a silly price.” It’s “a very good operator in a structurally tough industry, at a price that is fair if — and only if — you believe the cell shortage lasts long enough for Emmvee to keep compounding through the coming glut.” That is the one question the whole thing turns on, and we’ll interrogate it below.
Sitting down with the management
If Buffett and Agrawal sat across from D.V. Manjunatha for an afternoon, I think they’d like him — and they’d reserve judgement, because the public record is only seven months old.
Here’s who he is. Manjunatha started Emmvee in 1992 making solar water heaters — the “Solarizer” brand — because India’s morning power cuts left families without hot water [HARD, company release 2020-12-07]. He moved into solar panels around 2006, into cells in 2024, and built the company brick by brick over three decades without, until last year, ever touching the public’s money. That is the profile of a genuine owner-operator obsessed with his craft, not an asset-gatherer who discovered solar when it got fashionable. His stated philosophy — “technological advancement is the key to AtmaNirbhar Bharat in solar” [MEDIUM, interview 2021-02-22] — matches what the company actually did: it was an early mover into TOPCon and into the harder cell-manufacturing step, with a research tie-up with Germany’s Fraunhofer ISE since 2022 [MEDIUM]. Buffett’s “passion” test: pass.
On candor, the concalls are a pleasant surprise. When an analyst pushed on whether margins can hold, the CEO didn’t spin — he said don’t look at percentage margins, the per-watt price has always fallen and always will, watch the absolute spread (Q3 FY26 call, 2026-01-16). That is an unusually honest thing for a management to volunteer. The chairman’s first words as a listed company were about governance, internal controls and “sensible capital allocation, balanced leverage… moderate sustainable growth” (Q2 FY26 call, 2025-12-02). Talk is cheap, but it’s the right talk.
How have they spent the owners’ money? So far, well. The IPO (November 2025, ₹2,900 cr, priced at the top of the band) used ₹1,621 cr to pay down debt [HARD, RHP] — the single most shareholder-friendly use of fresh equity there is, and they executed it immediately. The big bet ahead is a 6 GW integrated cell+module plant at Devanahalli, ~₹5,500 cr, part-funded by an IREDA loan sanction of ₹3,306 cr, with management saying they may fund part from internal accruals to keep debt-to-equity below 1x. That’s disciplined intent. But it is intent, not track record — we have not yet seen this team allocate a large pot of public capital through a full cycle, and the next-generation CEO, Suhas (the founder’s son, Drexel 2019), has one career, all inside the family firm [HARD/MEDIUM]. The CFO, Pawan Kumar Jain, brings real outside experience (ex-CFO Aditya Birla Renewables) [MEDIUM], which helps.
Now the concerns, because there are real ones:
- A fresh customs penalty. In March 2026 the Bengaluru Customs Commissioner imposed ~₹7.7 cr (penalty + fine, including ₹44 lakh on a director/employees) for allegedly claiming undue preferential-duty benefits; the company plans to appeal [HARD, exchange disclosure 2026-03-17]. Small in rupees, but it’s a governance/process smudge in the first quarter as a public company, and worth watching.
- A subsidiary pledge. 51% of the cell subsidiary EEPL is pledged as loan security; a default could threaten control [HARD, DRHP risk factor]. No personal promoter equity pledge was found.
- Extreme concentration. The DRHP flags the top-10 customers at ~85–94% of revenue and ~95% of raw materials imported (over half from China). This is a business with very few, very large counterparties on both sides.
- Cash, not just profit. FY26 operating cash flow was ₹200 cr against ₹1,082 cr of reported profit, and free cash flow was negative ₹440 cr — because the company is pouring money into inventory and new plant. That’s normal for a fast-growing manufacturer, but it’s the opposite of the “fountain of cash” Buffett prizes, and it means the reported profit is real but not yet in the bank.
Would Buffett and Agrawal shake hands on this management? A provisional yes on the people, with the pen still hovering. The founder is the genuine article and the early capital allocation (debt repayment) was textbook. What would change their mind: any sign the customs matter is the tip of something larger, a single big quarter where reported profit again fails to become cash, or an empire-building lurch into wafers/ingots before the demand is proven. The honest verdict: admirable operators, unproven stewards of public money.
What’s on the horizon (live-issues tracker)
Three things will decide the next one to three years.
1. The cell-shortage window vs the coming cell glut — THE CRUX. Interrogated in full below. 🟡 Mixed/early — margins are holding superbly now (35–36% EBITDA), but the whole investment hinges on how long that lasts. Status amber not because anything is wrong today, but because the threat is structural and ahead of us.
2. The 6 GW Devanahalli expansion (capacity more than doubles). Emmvee plans to go from 10.3 GW modules / 2.94 GW cells today to 16.3 GW modules / 8.94 GW cells by H1 FY28 — roughly tripling cells. Land is acquired, financing (IREDA ₹3,306 cr) is closed, work has commenced (Q3 FY26 call). How it’s going so far: 🟢 on track — every milestone management set at the Q2 call (Sulibele lines commissioned, debt repaid, land payment done) was hit by the Q3 call. The two-sided read: if the cell shortage persists, this capacity is gold; if the glut arrives first, Emmvee will be commissioning a huge new plant straight into falling prices — the classic commodity-manufacturer trap. Next milestones: cell-line commissioning through FY27, full ramp by Mar–Apr 2027.
3. Backward integration into wafers and ingots. The next step up the chain, and the next ALMM mandate (List 3, ~June 2028) will require it. Management is deliberately not committing a timeline — they want clarity on the rule and the demand first (Q3 FY26 call). 🟢 sensible patience — Buffett would approve of a manager who refuses to over-build ahead of demand. But it’s a future call to make a large, complex, capital-heavy bet, and how they make it will tell us a lot about their stewardship.
The crux, interrogated
The crux in one sentence: This investment works if and only if India’s solar-cell shortage — and the policy walls protecting it — last long enough for Emmvee to keep earning uncommon per-watt margins while the rest of the industry races to flood the cell market.
First-principles mechanism — how the “moat” actually works. Emmvee’s high margin does not come from a brand or a switching cost. It comes from a physical scarcity created by law: from June 2026, government-linked solar projects must use Indian-made, ALMM-listed cells, and India today has only ~27 GW of cell capacity against ~210 GW of module capacity. So the cell is the bottleneck, and whoever owns the bottleneck collects the toll. Test the analogy: is this like owning the only bridge into a city? Not quite — it’s like owning one of the few bridges, while a dozen contractors are visibly building more bridges right next to yours. The toll is high today because the bridges are few; the toll falls as the bridges multiply. And in a commodity, the bridges always multiply. The mechanism that protects Emmvee (scarcity) is the exact mechanism the entire industry is spending billions to destroy.
Map the threat by name. The danger isn’t one rival — it’s the aggregate of capacity racing in.
| Threat / rival | Backed by / note | Cell capacity posture | Proof point |
|---|---|---|---|
| Waaree Energies | Largest Indian module maker, ₹90,000 cr mcap | Aggressively building integrated cell capacity | FY26 sales ₹26,537 cr — 5x Emmvee; scale advantage |
| Premier Energies | Established integrated cell+module player, ₹49,000 cr mcap | Already a major TOPCon cell maker | FY26 RoE 42%, OPM 30% — a true peer, ahead on scale |
| Adani Solar / Tata Power Solar | Deep-pocketed conglomerates | Integrated, expanding | Conglomerate balance sheets dwarf Emmvee’s |
| The long tail of new entrants | PLI scheme, cheap refurbished Chinese lines | ~12–15% of announced capacity stalled, per mgmt | Management’s own count: lots announced, much not built |
| Industry aggregate | — | India cell capacity → potentially ~140 GW by FY28 (mgmt cites this figure) | This is the glut that ends the toll |
Emmvee’s honest defence (Q3 FY26 call): making good cells is hard — TOPCon is a 14-step process needing semiconductor-grade clean rooms, and “experienced capacity” will beat “announced capacity.” That is true and it’s their real edge. But it’s a timing-and-quality advantage, not a permanent moat — it buys years, not decades.
The real-world precedent. We don’t have to guess — China already ran this movie. China built vast solar-cell and module capacity, the whole chain went into brutal oversupply, and prices and margins collapsed for everyone, even the best operators. The Chinese survivors are the lowest-cost, most-integrated, most-experienced players — which is precisely the bucket Emmvee is trying to be in. The lesson cuts both ways: a glut is coming (bearish), and the experienced low-cost integrated player is the one most likely to survive it (bullish). India’s twist is the policy wall (ALMM + duties) that China never had domestically — that wall could keep Indian margins higher for longer than China’s were. But walls built by regulators can be lowered by regulators.
Answered follow-on questions:
- Is the damage to share or to price? Mostly to price (per-watt margin), not share. Emmvee can probably keep selling — its quality and relationships protect volume. What erodes is the spread. So watch EBITDA-per-watt, not the order book.
- Which segment is hit first? Modules first, cells later. Modules are already in glut (210 GW capacity); cells are the protected, scarce link — which is exactly why Emmvee’s integration into cells is its single smartest move. The cell margin is the prize and the last to fall.
- What is Emmvee doing about it, and is it credible? Integrating deeper (cells now, wafers later) to own more of the scarce links, and competing on cost/quality. Credible — it’s the right strategy — but it’s the same strategy every serious rival is running.
- Has anyone moved yet? Not visibly — margins are still 35%+. The glut is anticipated, not arrived. That’s why the price is fair-not-cheap: the market is paying for today’s margin while knowing it’s borrowed time.
Honest view: This is not “too hard” — but it is genuinely two-sided and timing-dependent. The bull case (scarce cells + policy walls + best-in-class operator) and the bear case (commodity glut always arrives, margins always normalise) are both true — they just resolve on a clock we can’t read precisely. My read: Emmvee is very likely to survive and grow through the coming normalisation (the China precedent says the experienced integrated low-cost player makes it), but the 50%+ RoE and 34% margins are almost certainly a peak, not a baseline. Underwrite it as a good operator whose returns normalise toward (still-healthy but far lower) levels, not as a permanent super-profit machine.
The watch-list:
- EBITDA-per-watt (management’s own honest metric) — flat or rising = thesis intact; falling = glut arriving.
- India cell capacity additions vs the ~27 GW base — the speed of the glut.
- ALMM List-2 enforcement holding firm from June 2026 (no dilution, no carve-outs) — the wall.
- Devanahalli cell-line ramp on the Mar–Apr 2027 timeline (hits or slips).
- Operating cash flow converging toward reported profit (FY26 was ₹200 cr OCF vs ₹1,082 cr PAT — needs to close as growth capex peaks).
- Any escalation of the customs/duty matter beyond the ₹7.7 cr penalty.
QGLP scorecard (the Motilal Oswal lens) — the receipts
QGLP scores a stock on Quality, Growth, Longevity and Price. I translate each metric the first time. Business score is the /23 (Quality 12 + Growth 6 + Longevity 5); Price /2 is reported separately in its own section.
| # | Question | Score | Evidence |
|---|---|---|---|
| Quality of Business (Q1–Q6) | 4.5/6 | ||
| 1 | Large opportunity? | 1 | India targeting ~280 GW solar by 2030; ~60 GW/yr installs cited (Q2 call). Huge runway. |
| 2 | Industry structured favourably? | 0 | Fragmented commodity; 210 GW module capacity vs ~27 GW cell; price-taker (mgmt: “watch absolute, not % margin”). |
| 3 | Defensible moat? | 0.5 | Real cost/quality/experience edge (warranty <0.008%) + cell scarcity — but policy-rented and thin. RoE history too short to confirm 7-of-10. |
| 4 | High return ratios (RoE/RoCE >15%)? | 1 | RoE 51.1%, RoCE 44.8%; RoCE 28%→45% (FY24→FY26) — ratios_table. Both far above 15% now. |
| 5 | Asset-light / low capital intensity? | 0 | Capital-hungry: FCF negative ₹440 cr (FY26), heavy capex; fixed assets ₹291cr→₹2,634cr in two years. A “Good”, not a “Great”, boat. |
| 6 | Favourable terms of trade (negative working capital)? | 0 | Working-capital days flipped −38 → +88; debtor 50d, inventory 225d, payables 116d — it banks its suppliers’ patience, not the other way round. |
| Quality of Management (Q7–Q12) | 3/6 | (scored cautiously — only 7 months of public record) | |
| 7 | Unquestionable integrity? | 0.5 | No major scandal; founder credible. But fresh ₹7.7 cr customs penalty (Mar 2026) + 51% subsidiary pledge are smudges. |
| 8 | Proven execution? | 1 | 30-yr operating history; hit every Q2-call milestone by Q3; rapid TOPCon ramp. Operationally excellent. |
| 9 | Growth mindset & vision? | 0.5 | Clear ambition (triple cells, integrate to wafers) — but deliberately unproven on the next big bet. |
| 10 | Superior capital allocation? | 0.5 | Textbook debt repayment with IPO proceeds; but no full-cycle public track record yet, and heavy capex ahead. |
| 11 | Clear succession? | 0.5 | Son (Suhas) as CEO + outside CFO; intra-family, thin standalone bench. Key-man risk on founder. |
| 12 | Minority interests protected? | 0 | No dividend policy yet, 80% promoter holding, just-listed; nothing demonstrated to minorities so far. |
| Growth (Q13–Q18) | 5/6 | ||
| 13 | Structural tailwind > 1.5× GDP? | 1 | Solar capacity additions growing far faster than GDP; ALMM + DCR mandates are direct demand creators. |
| 14 | Volume-led, not just price? | 1 | Pure volume (capacity) story — prices are falling; growth is all watts shipped. |
| 15 | Operating leverage? | 1 | OPM 9% (FY23) → 13% → 31% → 34% (FY26) as sales scaled — profit_loss. Textbook leverage. |
| 16 | Manageable, accretive leverage? | 1 | Post-IPO borrowings ₹2,065cr → ₹360cr; D/E now ~0.1x. De-risked. |
| 17 | Market-share gain potential? | 1 | Scarce cell side + ALMM tailwind; integrated player gaining vs module-only rivals. |
| 18 | Earnings growth > 15% CAGR? | 0 | PAT CAGR is astronomical trailing (₹9cr→₹1,082cr in 3 yrs) — but it’s off a tiny base and from a cyclical peak; not scoreable as durable 15%+. Marking conservatively. |
| Longevity (Q19–Q23) | 2/5 | ||
| 19 | Relevant in 10–15 years (low disruption)? | 1 | Solar demand is structural and durable for decades. The product is here to stay. |
| 20 | Can it extend its moat (CAP)? | 0 | Commodity; the high-return period (CAP) is the opposite of widening — the glut narrows it. |
| 21 | Can it sustain its growth runway (GAP)? | 0.5 | Long demand runway, but margins/returns won’t stay at peak; growth yes, super-profit growth no. |
| 22 | Headroom for diversification? | 0.5 | Backward integration (wafers/ingots) + exports give optionality — unproven. |
| 23 | Adaptive, resilient culture? | 0 | No public record through a down-cycle yet; the only test is ahead (the glut). Default low on no evidence. |
| Business-quality total | 14.5 / 23 | Quality 7.5 · Growth 5 · Longevity 2 | |
| Price (Q24–Q25, separate) | 1 / 2 | PEG ~0.85x forward; payback ~1.8–2.4x. See price section. | |
| (canonical QGLP /25, for fidelity) | 15.5 / 25 |
The pillar pattern: Growth is the blazing strength (5/6) and Quality is decent today (high returns, great operator). But Longevity is the weak pillar (2/5) — and in this framework, longevity is everything, because it asks whether the high returns last. The score says, plainly: a wonderful present, an uncertain durability.
Buffett lens (the Berkshire-letters read)
| # | Test | Result | Evidence / Buffett line |
|---|---|---|---|
| 1 | Good boat? (business > management) | PARTIAL | ”A good managerial record is far more a function of what business boat you get into.” Solar manufacturing is a Good, capital-hungry boat — not a Great one. |
| 2 | Moat + franchise + pricing power | FAIL | A franchise can “price aggressively.” Emmvee is a price-taker — mgmt explicitly says per-watt prices always fall. No pricing power; margin is rented from scarcity. |
| 3 | See’s test — high returns on little capital | FAIL | The opposite of See’s: FCF −₹440 cr (FY26), capex devours cash. Growth eats capital. |
| 4 | Capital allocation — one-dollar test | PARTIAL | Early signs good (IPO → debt repayment). But no full-cycle track record; the big capex test is ahead. Provisional. |
| 5 | Owner-oriented, candid management | PASS | Genuinely candid concalls (“don’t look at % margin”); founder-operator; honest about risks. “We eat our own cooking” — 80% promoter holding. |
| 6 | Integrity / no “credit P&L, debit balance sheet” | PARTIAL | Profit is real but not yet cash (OCF ₹200cr vs PAT ₹1,082cr; receivables/inventory swelling). Plus the customs penalty. Watch closely. |
| 7 | Circle of competence / predictability | FAIL | ”If there’s lots of technology, we won’t understand it.” TOPCon → G12R → wafers: tech-fragile, fast-moving, hard to predict 10 yrs out. |
| 8 | Mr. Market — gift or trap now? | PARTIAL | Not euphoric (flat listing), not fearful; fair-to-warm. Quality at a fair price, not a fearful one. |
| 9 | Patience / compounding runway | PARTIAL | Long demand runway, but compounding at 50% RoE is not durable — returns normalise. Good runway, fading return. |
| 10 | The honest red flag | (see below) | The single strongest bear point, stated in full. |
Tally: 3 PASS + 2 PARTIAL = ~4/10. A real business with real gaps — well short of Buffett-grade, mainly because tests 2, 3 and 7 (moat, capital-lightness, predictability) are the ones the letters weight hardest, and Emmvee fails all three.
The See’s test, spelled out. See’s Candy was magic because it earned huge returns while swallowing almost no extra capital — $32m of reinvestment over 35 years threw off $1.35bn. Emmvee is the mirror image: to grow profit it must keep building billion-rupee factories. FY26 free cash flow was negative ₹440 cr even as reported profit hit ₹1,082 cr, because every rupee (and more) went into inventory and new plant. That’s not a criticism of the management — it’s the nature of the boat. It is why this is a “Good” business, not a “Great” one: the returns are high but they don’t come free.
The one-dollar test, spelled out. Has each rupee retained created at least a rupee of market value? So far, spectacularly yes — but the history is too short to bank. The honest version: the IPO rupees were used wisely (debt repayment, immediately accretive). The next ₹5,500 cr — the Devanahalli plant — is the real test, and it will land into a market that may have far more cell capacity than today. Whether that rupee makes a rupee depends entirely on the crux above. Verdict: passes on the evidence we have, unproven on the evidence that matters most.
The framework metrics
- Economic Profit = Net Worth ₹3,694 cr × (RoE 51.1% − CoE 12%) = +₹1,444 cr. Hugely positive — genuine super-profit today. (CoE assumed 12%.) But this rests on a peak RoE; normalise RoE to, say, 25% and EP halves — still positive, but the headline number is a cyclical high.
- Terms of Trade = a proxy from days (debtor 50 ÷ payable 116) ≈ 43%, which looks favourable — but the truer read is that working-capital days flipped from −38 to +88 as inventory ballooned to 225 days. The business now funds a large working-capital pile (cells/wafers stocked ahead of orders). Not the negative-working-capital cash engine QGLP prizes.
- 5-yr Payback = Mcap ₹22,993 cr ÷ projected cumulative 5-yr PAT. At a (generous) 30% PAT CAGR ≈ 1.8x; at a more sober 20% ≈ 2.4x. Above the <1x multi-bagger signal — you are not getting paid back from earnings inside five years at this price. (Assumption stated: 20–30% forward PAT CAGR off the FY26 base.)
- PEG = P/E 21.3 ÷ growth. On trailing hyper-growth it’s a meaningless ~0.1x; on a sane normalised forward 25%, PEG ≈ 0.85x — which does clear the <1x discipline. The two payback/PEG signals disagree, which is itself the message: cheap on near-term growth, dear on a 5-year cash-back basis.
- RoE − CoE spread = +39 percentage points today — enormous, but only ~2–3 years of public history above 15%, so the “≥7 of 10 years” durability test cannot yet be passed (data pending — pre-IPO years FY20–23 showed RoCE of 6–9%, i.e. the high returns are recent).
- Consistent vs Volatile = Volatile. PAT was ₹14cr→₹9cr→₹13cr→₹9cr→₹29cr→₹369cr→₹1,082cr (FY20–FY26): falls in multiple years, a near-flat low-profit decade, then an explosive ramp. By WCS-27 rules this is clearly a Volatile earner (value on P/B, treat P/E with suspicion) — not a steady compounder.
Peer comparison
Mandatory. The closest listed peers are the other integrated Indian solar cell+module makers.
| Company | Mkt cap (₹cr) | CMP (₹) | P/E | P/B | RoE | RoCE | OPM | FY26 Sales (₹cr) |
|---|---|---|---|---|---|---|---|---|
| Emmvee | 22,993 | 332 | 21.3 | 6.2 | 51.1% | 44.8% | 34% | 5,050 |
| Waaree Energies | 89,903 | 3,125 | 22.9 | 6.2 | 32.8% | 38.8% | 22% | 26,537 |
| Premier Energies | 49,009 | 1,080 | 32.5 | 11.4 | 42.4% | 33.3% | 30% | 7,824 |
| Websol Energy | 4,546 | 105 | 15.0 | 7.2 | 66.9% | 63.2% | 41% | 1,049 |
All from each peer’s screener snapshot, 2026-06-20.
The relative read flips the absolute one — partly. On the QGLP absolute price bar (payback >1x), Emmvee looks demanding. But relative to its own asset class, Emmvee is the cheapest of the big two integrated peers — 21.3x P/E vs Waaree’s 22.9x and Premier’s 32.5x, while posting the highest margin (34% OPM) and the highest RoCE (44.8%) of the large trio. It’s smaller than Waaree (1/5 the sales) and Premier, which is the catch — less scale, more concentration risk. Tiny Websol screens cheaper still (15x) at even higher returns, but it’s a fraction of the size and a different risk profile. Net: within the solar-manufacturing aisle, Emmvee is priced reasonably for the best margins — a sector-allocator could justify it over Premier on valuation. The two readings answer different questions: the patient value-investor (absolute payback) says “rich”; the sector-allocator (relative) says “the cheapest quality name in a hot aisle.” Both are honest.
Latest quarter & what’s happening now
Q3 FY26 (quarter to Dec 2025, reported 2026-01-16): revenue ₹1,152 cr (+118% YoY), EBITDA ₹413 cr (35.9% margin), PAT ₹264 cr (+166% YoY). Order book 9.3 GW including a 4.5 GW multi-year TOPCon cell order; module capacity now 10.3 GW. The just-reported Q4/FY26 full year (per screener): sales ₹1,739 cr in Q4, full-year sales ₹5,050 cr, PAT ₹1,082 cr, OPM 34%.
Concall takeaways: (1) margins held at ~35–36% despite a silver-price spike, because process R&D cut silver-paste use sharply and most contracts are pass-through — a genuine cost-engineering edge; (2) management is deliberately not over-booking orders (“we don’t want to take more than we can execute in 12–18 months”) — disciplined, not land-grabbing; (3) wafer/ingot integration is on the radar but un-timed pending the ALMM List-3 rule (~June 2028). Live catalysts: ALMM List-2 cell mandate from June 2026 [HARD], Devanahalli 6 GW ramp by Mar–Apr 2027 [MEDIUM], China export-rebate removal from April 2026 (mild tailwind for Indian makers) [MEDIUM/SOFT].
Where the two lenses agree — and disagree
They agree on the big picture: both score Emmvee as a Good, not Great business — high returns now, but capital-hungry, commodity-exposed, and short on durable moat. QGLP’s weak Longevity pillar (2/5) and Buffett’s failures on tests 2/3/7 (moat, See’s, predictability) are saying the same thing in two languages: the current super-returns are not structurally protected.
Where they part company is subtle and worth flagging: QGLP’s Growth pillar lights up green (5/6) — and a pure checklist could let that growth score flatter the overall read. Buffett’s lens is harsher precisely here: his test 7 (circle of competence / predictability) fails the same growth that QGLP rewards, because it’s tech-fragile commodity growth he wouldn’t underwrite for ten years. Trust the Buffett flag. The divergence is the signal: this is a company whose growth is easy to love and whose durability is the thing to doubt. The QGLP number (14.5/23) and the Buffett bucket (Good, ~4/10) are consistent — both land on “good operator, watch the moat.”
The price as a current phenomenon
This section judges the price, not the business. Box 1 is already settled; here we only ask what Mr. Market is charging today.
The margin-of-safety band: roughly ₹180–₹250. This is where the framework’s arithmetic gets comfortable — where the 5-year payback feel moves toward ~1x on a sober growth assumption and PEG sits clearly below 1x on normalised (not peak) earnings. It is a band, not a point, and it sits below the current ₹332 — which simply says today’s price already embeds continued strong growth. Note this band is wide because the earnings base is itself uncertain (a cyclical peak is a treacherous thing to value off).
The Mr.-Market read. The stock ran from a ₹172 low to ₹354 — a hard re-rating, driven almost entirely by the June-2026 ALMM cell-mandate tailwind and the clean post-IPO balance sheet. But the mood is fair-to-warm, not euphoric: the IPO listed flat (0% pop, near-fully-but-not-blowout subscribed), FIIs trimmed slightly (3.97%→2.45% over the quarter), and the P/E (21x) is undemanding for the growth. So the patsy question — “who’s the greater fool at this price?” — doesn’t scream the way it does in a hype name. The risk here isn’t that you’re buying euphoria; it’s that you’re buying peak-cycle margins at a fair multiple, and the multiple looks fair only because the E is at a high.
The tension, plainly: a Good business at a fair-to-slightly-rich price. Not the Buffett dream (a wonderful business at a fearful price), not the value-trap nightmare (a gruesome business cheap). It is the middle case — pay a fair price for genuine quality, and accept that the quality’s returns are likely near a peak. Remember: this reading can flip next week — a crack in module prices, an early cell glut, or a wobble in the ALMM rule — without one thing in Box 1 changing.
Conviction texture
The bull case, at its strongest: Emmvee is the right factory in the right country at the right moment. India has legislated demand for exactly what it makes (Indian TOPCon cells), it’s one of few who make them well, it just cleaned its balance sheet, it earns the best margins of the big integrated peers, and it trades at a discount to them. The China precedent says the experienced, low-cost, integrated operator is the one who survives the coming glut — and Emmvee is squarely that operator. If the cell shortage lasts even three or four more years, the Devanahalli capacity prints money and the stock looks cheap in hindsight.
The bear case, at its strongest: This is a commodity manufacturer at peak margins, and commodities always revert. India’s cell capacity could quintuple by FY28; when it does, the 35% EBITDA margin and 50% RoE — the entire basis of today’s valuation — normalise toward ordinary manufacturing returns. The moat is rented from a regulator, not owned. The business doesn’t generate free cash (it consumes it), reported profit isn’t yet in the bank, customer/supplier concentration is extreme, China supplies the inputs, and there’s a fresh customs penalty in the first quarter as a public company. You’d be valuing the boat at high tide.
What the numbers actually support: a Good operator, genuinely excellent at its craft, earning cyclically peak returns it is unlikely to sustain at this level — fairly priced versus peers, demanding on an absolute cash-payback basis. Three things to watch that tip it: (1) EBITDA-per-watt — flat = thesis holds, falling = glut arriving; (2) operating cash flow converging toward reported profit; (3) the ALMM cell mandate holding firm from June 2026. No buy/sell/hold here — the deliverable is the picture, and the picture is a good company in a hard industry at a fair price, with the durability question genuinely open.
Sources
- Screener snapshot (FY26 full year, quarterly, balance sheet, cash flow, shareholding): https://www.screener.in/company/EMMVEE/consolidated/ — fetched 2026-06-20.
- Concall transcripts: Q3 FY26 (call 2026-01-16) and Q2 FY26 (call 2025-12-02), filed with BSE/NSE.
- DRHP/RHP & IPO (Nov 2025, ₹2,900 cr, ₹1,621 cr to debt repayment), promoter/management background, customs penalty (Mar 2026), warranty-claim and sector/ALMM context: web research, dated and tagged HARD/MEDIUM/SOFT in the management dossier.
- Peers (Waaree, Premier Energies, Websol): screener snapshots, 2026-06-20.
- Assumptions: Cost of Equity (CoE) = 12%; forward PAT CAGR for payback = 20–30% off the FY26 base (peak-cycle base, treated cautiously). Data caveat: no annual reports yet (listed Nov 2025); long-history durability tests marked provisional.